oltipraz has been researched along with Urinary Bladder Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, G; Wang, X | 1 |
| Akaza, H; Hattori, K; Iida, K; Itoh, K; Kawai, K; Kumagai, Y; Oyasu, R; Shimazui, T; Yamamoto, M | 1 |
1 review(s) available for oltipraz and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
[Development of bladder cancer chemoprevention].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Papillary; Humans; Neoplasm Recurrence, Local; Piroxicam; Pyrazines; Retinoids; Thiones; Thiophenes; Urinary Bladder Neoplasms | 2003 |
1 other study(ies) available for oltipraz and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; DNA-Binding Proteins; Enzyme Induction; Female; Gene Expression; Genetic Predisposition to Disease; Glucuronides; Glucuronosyltransferase; Inactivation, Metabolic; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Microsomes, Liver; NF-E2-Related Factor 2; Pyrazines; Thiones; Thiophenes; Trans-Activators; Urinary Bladder; Urinary Bladder Neoplasms | 2004 |